Kornimate/medical-research-clean huggingface dataset:
evaluation of tar technique in the treatment of huge abdominal wall hernia and large abdominal wall defect with or without botox injection .

Conditions: TAR Technique

Summary: aim of the work in this study, we will evaluate posterior component separation (tar) technique with or without botox injection for open huge ventral hernia and large abdominal wall defect repair. the primary outcome will be recurrence while the secondary outcome will be infection, postoperative complications (bleeding and dehiscence), pain score, operative time, hospitalization, need for drain, time for drain removal and pulmonary function test before and after surgery. this prospective clinical study will be performed on 40 eligible patients admitted to general surgery department at mansoura university hospi


Eligibility criteria:
inclusion criteria: * adult patient fit for general anesthesia with huge ventral hernia (primary, incisional or recurrent).any patient with large abdominal wall defect secondary to abdominal wall tumor excision or burst after surgery exclusion criteria: * patients who are unfit for general anaesthesia. poor pulmonary function tests. pregnant females. patient younger than 18 years. immunodeficiency. patient with psychiatric disease disabling surgical intervention. patients who refuse to participate in our study.
albumin-bound paclitaxel and bevacizumab for platinum-resistant recurrent ovarian cancer

Conditions: Ovarian Carcinoma; Platinum-resistant Ovarian Cancer; Recurrent Ovarian Carcinoma; Albumin-bound Paclitaxel; Bevacizumab; Survival Outcomes; Adverse Events

Summary: this study is a prospective, multicenter, phase ii clinical trial to evaluate the efficacy and safety of albumin-bound paclitaxel combined with bevacizumab for platinum-resistant recurrent epithelial ovarian cancer. patients with platinum-resistant recurrent ovarian cancer who meet the inclusion criteria, and don't meet any of the exclusion criteria, are enrolled in the study. they will receive albumin-bound paclitaxel (260 mg/m2) and bevacizumab (7.5mg/kg) intravenously every 21 days. treatment continue until disease progression, intolerable toxicity, or patient refusal. objective response rates primary objective. progression-free survival, overall survival, and safety are secondary objectives. the study will enroll a total of 50 patients.


Eligibility criteria:
inclusion criteria 1. aged 18\~75 years old 2. histologically confirmed platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer 3. at least one measurable lesion according to the response evaluation criteria in solid tumors (recist) 1.1 4. eastern cooperative oncology group (ecog) performance status score of 0-2; 5. sufficient bone marrow function; 6. sufficient liver and renal function; 7. patients of reproductive potential were required to take effective contraceptive measures for the duration of the study and had a negative serum or urine pregnancy test result; non-lactating women; 8. patients had no disturbance of consciousness and volunteered to participate in the study. exclusion criteria 1. uncontrolled hypertension 2. tumor invading vital blood vessels 3. with contraindications to chemotherapy 4. with uncontrolled infection 5. patients had received anticancer therapy within 3 weeks before enrollment 6. patients were allergic or intolerant to investigational drugs or its ingredients 7. patients are not suitable for this trial as judged by investigators
acute heart failure - congestion discharge evaluation

Conditions: Acute Heart Failure

Summary: acute heart failure (ahf) is a major public health problem, associated with a 40% risk of death or re-hospitalisation at 3 months. this risk is significantly increased by insufficient decongestion at the end of hospitalisation for ahf assessed by a standardised clinical score, a natriuretic peptide dosage or by cardiac and pulmonary ultrasound . adapting treatment according to lung congestion assessed by implantable devices (not reimbursed in france) improves the prognosis. however, due to the lack of a standardised congestion assessment, therapeutic adaptation in acute heart failure is currently empirical. the best multimodality approach to congestion evaluation is uncertain.


Eligibility criteria:
inclusion criteria: * patients hospitalised for acute heart failure. * patients considered clinically discharging from hospitalisation for acute heart failure. * age ≥18 years * patients having received complete information regarding the study design and having signed their informed consent form. * patient affiliated to or beneficiary of a social security scheme. exclusion criteria: * comorbidity for which the life expectancy is ≤ 3 months * dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular filtration rate \<15 ml/min/m2 at inclusion. * history of lobectomy or pneumonectomy lung surgery * severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc. * pregnant woman, parturient or nursing mother * adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice) * adult person who is unable to give consent * person deprived of liberty by a judicial or administrative decision, * person subject to psychiatric care pursuant to articles l. 3212-1 and l. 3213-1 of the public health code.

Keywords: acute heart failure
dance therapy and obesity

Conditions: Obesity

Summary: title: the effect of dance-therapy on the functional capacity, body image and quality of life of patients with advanced obesity project duration: 33 months (august 2010 to june 2013) clinical context: obesity has reached epidemic proportions. the gait and balance problems in obese people and the associated decreased functional capacity and risk of falling highlight the need to evaluate the benefits of specific treatments on these problems. attention should be paid not only to metabolic management but also to the physical rehabilitation required in cases of advanced obesity. objectives: the aim of this study is to evaluate the efficacy of dance-therapy on functional capacity (walking ability, postural control and physical activity level), body image and quality of life of patients with advanced obesity.


Eligibility criteria:
inclusion criteria: * person with obesity (bmi ≥ 30) * aged \> 18 years old * being able to walk 10 meters without a walking aid exclusion criteria: * foot ulcer at the moment of data acquisition * orthopaedic, surgical or neurological (other than diabetic neuropathy ) problems which af-fect patient's gait * non diabetic neuropathy (charcot, chronic alcohol consumption, thyroid dysfunction) * mental diseases interfering with group therapies

Keywords: obesity dance gait balance posture dance therapy
a randomized control trial assessing the effect of topical tranexamic acid on risk of hematoma in breast surgery

Conditions: Hematoma Postoperative

Summary: this trial is being completed to evaluate the safety and efficacy of topical tranexamic acid use in preventing hematomas in routine breast plastic surgery operations.


Eligibility criteria:
inclusion criteria: * patients undergoing bilateral breast reduction or bilateral gender-affirming mastectomy * for patients undergoing bilateral breast reduction, any skin incision pattern or pedicle is acceptable. * for patients undergoing bilateral gender-affirming mastectomy, any skin incision and mastectomy type is acceptable exclusion criteria: * active thromboembolic disease or history of intrinsic risk of thrombosis or thromboembolism, including retinal vein or artery occlusion * current use of systemic anticoagulation * hypersensitivity to tranexamic acid * concomitant use of combined hormonal contraceptives * use of factor ix complex concentrates, anti-inhibitor coagulant concentrates or all-trans retinoic acid * history of acquired defective color vision * history of subarachnoid hemorrhage * pregnancy * history of renal impairment or serum creatinine \>1.5 milligrams per deciliter (mg/dl)

Keywords: breast reduction gender-affirming mastectomy tranexamic acid
pf-00489791 for the treatment of raynaud's

Conditions: Raynaud's Disease; Peripheral Vascular Disease

Summary: the investigators propose that once daily administration of pf-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with primary and secondary raynaud's phenomenon.


Eligibility criteria:
inclusion criteria: * active raynaud's phenomenon * stable disease and medication requirements over the previous two months * for secondary raynaud's phenomenon subjects, a diagnosis of scleroderma using the american college of rheumatology criteria or by the presence of at least 3/5 features of crest syndrome * both sexes exclusion criteria: * uncontrolled hypertension, diabetes mellitus, angina, or using oral nitrates * smoking within 3 months or smoking cessation using nicotine products * subjects currently taking sildenafil, tadalafil or vardenafil * subjects with ulnar arterial occlusive disease as shown by a modified allen test * pregnant or breast feeding or considering pregnancy in next 4 months * participation in trial for investigational drug within 30 days

Keywords: raynaud's phenomenon vasospasm scleroderma systemic sclerosis crest phosphodiesterase inhibitor
immediate versus early (24-hours) urinary catheter removal after elective minimally invasive colonic resection

Conditions: Surgical Complication; Colonic Disease; Postoperative Complications; Urinary Retention Postoperative; Urinary Tract Infections

Summary: the primary aim of this study is to compare the rate of acute urinary retention (aur) after immediate compared to early (24-hours) removal of urinary catheter (uc) in patients undergoing minimally invasive colorectal resection. the study hypothesis is that immediate uc removal is non-inferior to 24-hours uc removal in terms of aur rate. the secondary outcomes focus on goals that could be positively impacted by the immediate removal of the uc at the end of the surgery. in particular, the rate of urinary tract infections, perception of pain, time-to-return of bowel and physical functions, postoperative complications and postoperative length of stay will all be measured.


Eligibility criteria:
inclusion criteria: 1. age between 18 years and 80 years old 2. patients scheduled to undergo minimally invasive resection of the colon under general anesthesia 3. willingness to participate 4. compliance to study purpose 5. written informed consent exclusion criteria: 1. need for an anastomosis below the anterior peritoneal reflection 2. need for a major resection other than colorectal 3. need for post-operative intensive care monitoring or intensive care unit (icu) stay 4. anesthesia time longer than 300 minutes 5. presence of chronic indwelling uc 6. presence of an entero-vesical fistula 7. need for ureteral stent placement, bladder resection or repair 8. a previous and unsolved history of aur or overt voiding dysfunction
quantitation of glymphatic functioning in sleep and meditative states

Conditions: Parkinson Disease; Sleep

Summary: this involves development and application of magnetic resonance imaging (mri) methods for visualizing hemodynamic and metabolic relationships in healthy volunteers with advanced meditation experience.

this study is evaluating the glymphatic system during awake, sleep, and meditative states.

Eligibility criteria:
inclusion criteria: * ages 14-45 * "adept meditator status" exclusion criteria: * any non-mr compatible material implant, or contraindication to mr scanning * claustrophobia or inability to lie still for prolonged periods of time * participants with a recent (less than 2 months) infection, tattoo, or wound * no consumption of stimulants or alcohol within 12 hours of the study visit * clinical diagnosis of any major neurological or psychological condition * taking benzodiazepines, cholinestorase inhibitors, anti-psychotics, opioids, mao inhibitors

Keywords: glymphatic system meditation
a randomized controlled trial to evaluate the effectiveness of bleomycin and cryotherapy in treating plantar warts.

Conditions: Verruca Plantaris

Summary: to evaluate the efficacy of bleomycin and cryopreservation in the treatment of plantar verruca by dermoscopy and explore the influencing factors. compare the safety, economic burden and impact on quality of life of the two treatments

our research aims to evaluate and compare the effectiveness of bleomycin and cryotherapy in treating plantar warts. first, we enrolled patients according to eligibility criteria. second, the patients were assigned to two groups randomly. one is bleomycin group and the other is cryotherapy group which means two -group-patients were received different therapies. thirdly, we compared the efficiency of two groups by using dermoscopy. finnally, we used statistical analysis to analyze the research data and draw the experimental conclusions.

Eligibility criteria:
inclusion criteria: age 18-65 years old, gender is not limited; consistent with the diagnosis of plantar warts; volunteer for treatment and sign informed consent; consent to photograph the lesion; the treatment target area can be selected (the target area must meet the following conditions: the distance between adjacent warts in the target area is \>0.5cm; the diameter of a single wart in the target area is ≤1.5cm, and/or the diameter of a wart mass is ≤1.5cm; the number of total warts/wart masses in the target area is ≤10). exclusion criteria: patients who can't sign informed consent; had previously received local treatment for common warts within 1 month; hiv-positive patient; pregnant and lactating women; has peripheral vascular disease; allergic to bleomycin; people who are severely immunocompromised, or who are taking immunosuppressive drugs; mental illness or cognitive incapacity; other conditions deemed unsuitable for inclusion, such as inability to cooperate with follow-up, were considered by the researchers.

Keywords: verruca plantaris bleomycin cryotherapy efficiency security
short- and long-term health effects of air pollution in poland

Conditions: Acute Coronary Syndrome; Atrial Fibrillation; Kidney Diseases; Particulate Matter Inhalation Injury; Pollution; Exposure; Oxidative Stress; Ischemic Stroke

Summary: the effects of air pollution on the frequency of hospital admissions and mortality due to acute coronary syndromes, atrial fibrillation, and renal disfunction are noted also in areas perceived as pollution-free (due to the lack of large industry). the aim of the project is to assess the impact of air pollution in eastern poland on regional public health.

the project will be conducted in eastern poland - the area characterized by unique natural features, large areas covered by forests, lack of factories, and relatively low industrialization. on the other hand, the region is also characterized by low socioeconomic status, in the cold season the residents' suboptimal heating choices are in result posing a major anthropogenic threat to air quality in the form of low emissions. the vast majority of studies on air pollution were conducted in highly polluted areas, in which patients are exposed to moderate and extreme concentrations of pollutants. taking into consideration the scarce number of surveys from areas with a low level of pollution the investigators intend to analyze the relationship between air pollution and cardiovascular and renal outcomes in eastern poland. the examination of the impact of so-called "polish smog" on mortality and morbidity in the study area is not without significance. it would be the first major study of the impact of this type of pollution on human health. in the subsequent part of the study, we will evaluate the effects of polish smog in the entire country. in light of extant body of literature, the following will be considered as the public health indicators: acute coronary syndromes, episodes of atrial fibrillation, ischemic strokes, kidney disease hospitalizations or emergency room visits, cardiovascular and renal mortality.

Eligibility criteria:
inclusion criteria: * residents from the analyzed area exclusion criteria: * none

Keywords: air pollution public health acute coronary syndromes atrial fibrillation kidney diseases particulate matter cardiovascular diseases
a glucometabolic evaluation of patients with idiopathic ketotic hypoglycemia

Conditions: Idiopathic Ketotic Hypoglycemia

Summary: the project will evaluate 1) the postprandial metabolism and 2) continuous glucose levels in subjects diagnosed with idiopathic ketotic hypoglycemia (ikh)) and healthy control subjects.

ikh is a common, but not fully understood, condition in children, and in some the condition may persist in adulthood. in the present study we seek to evaluate the postprandial metabolism in adult subjects diagnosed with ikh through a clinical study including: 1. two test days, where the subjects completes a) an oral glucose tolerance test (ogtt) and b) a miced meal test (mmt). before, during and after ingestion of the ogtt/mmt, blood samples will be frequently drawn for the evaluation of plasma glucose, hormones, amino acids and more. during both tests, the subjects will recieve a continuous infusion of primed glucose tracer to further evaluate the glucose metabolism. 2. a 14-day period where the subjects will lead the usual lives, wearing a continuous glucose monitor (cgm). this will enable us to evaluate long-term differences in plasma glucose levels in ikh.

Eligibility criteria:
inclusion criteria: * ikh-participants: * verified diagnosis of ikh by health professional * bmi of 18-30 kg/m2 * normal liver- and kidney function * informed consent healthy control participants * normal glucose tolerance * bmi of 18-30 kg/m2 * normal liver- and kidney function * informed consent exclusion criteria: * a history of diabetes * close family members with diabetes * use of drugs affecting the glucose metabolism that cannot be paused * anemia * any condition that the study investigators deem unacceptable for participation * pregnancy or breastfeeding.

Keywords: idiopathic ketotic hypoglycemia glucose metabolism gut homones amino acids glucagon insulin continuous glucose monitor cgm oral glucose tolerance test mixed meal test
efficacy and tolerability of sub-anesthetic ketamine in postpartum depression

Conditions: Post Partum Depression

Summary: postpartum depression is a non-psychotic major or minor depressive episode that occurs during pregnancy or within 12 months of post-partum period. the nature of symptoms is same as depressive episode characterized by depressed mood, anxiety, sleep difficulties, suicidal thoughts, tiredness and diminished interest in pleasurable activities. severe maternal depression affects children by increasing the risk of emotional and behavioral and physical health problems and cognitive difficulties. thus early screening and intervention is critical in reducing the negative impact of pnd in the mother and child, family and the community. the purpose of this study is to assess the safety, pharmacokinetics and antidepressant efficacy of sub-anesthetic dose of intravenous ketamine in perinatal depression.


Eligibility criteria:
inclusion criteria: * female subjects, ages 18-45 years * experienced a major depressive episode in the postpartum period beginning within the first 4 weeks following delivery and with moderate or severe symptoms (\>12 epds or \>14 ham-d). * no or partial response to adequate doses of ssri medications to treat pnd for longer than 6 weeks. * pnd patients will be requested to maintain the stable dose of antidepressants while enrolled in the study trial. * patients that can speak and read the english language, are able to understand the study procedures and sign the informed consent exclusion criteria: * no current or past psychosis or severe personality disorder. * no current substance abuse or dependence. * no serious and imminent suicidal or homicidal risk. * no recent or history of major and unstable medical problems that affect brain anatomy, neurochemistry, or function. * not diagnosed with cardiovascular disorders. * no increased risk of laryngospasm or active upper respiratory infections. * not diagnosed with an intellectual disability or neurodegenerative diseases. * mothers that are currently breastfeeding. * no current pregnancy.
a study to evaluate growth in participants treated with somatropin (nutropin) using nuspin device

Conditions: Growth Hormone Deficiency

Summary: this is a phase iv, open label, case-controlled, observational study to evaluate the age-adjusted cumulative height velocity in pre-pubertal isolated growth hormone deficient (ighd) and idiopathic short stature (iss) participants receiving daily doses of somatropin (recombinant human growth hormone \[rhgh\]; nutropin) using nuspin device compared to historical controls from the national cooperative growth study (ncgs).


Eligibility criteria:
inclusion criteria: * bone age less than or equal to (\</=) 8 years (females) or \</= 10 years (males) as determined by x-ray of the left hand and wrist obtained within six months before enrollment * prepubertal males and females by physical exam * naive to rhgh therapy * diagnosis of ighd or iss by standard pharmacologic testing and no other discernable etiology for short stature * height standard deviation score (ht sds) \</= -1.5 (\</= 5th percentile) for ighd participants; ht sds \</= -2.25 (\</= 1.2 percentile) for iss participants exclusion criteria: * short stature etiologies other than ighd or iss * participants receiving chronic corticosteroid therapy (greater than \[\>\] 3 months) for other medical conditions * participants with active malignancy or any other condition that the investigator believes would pose a significant hazard to the participant if rhgh were initiated * females with turner syndrome * any previous rhgh treatment * participation in another simultaneous medical investigation or trial * pediatric participants with closed epiphyses * participants prescribed rhgh doses outside the variance of ncgs control participant dosing
comprehensive evaluation of visual function

Conditions: Visual Function

Summary: the purpose of this study is to assess the level of visual functioning in patients with various eye conditions while wearing different types of eyeglasses.

the purpose of the research is to study the level of visual functioning in individuals with various eye conditions when using different types of eyeglass lenses. therefore, the goal of this study is to determine factors that may account for variability in the visual functioning of individuals with a range of refractive errors and their ability to perform everyday activities when equipped with different types of lenses. we hypothesize that the subjects will perform visual tasks of function better when using izon™ wavefront-guided glasses than with conventional glasses. this hypothesis is based upon the glasses yielding better visual acuity and because the design of the glasses reduces the effects of glare. this research is important so that alternate treatments and vision correction may be implemented which will have a more beneficial impact on those with refractive errors and visual impairment.

Eligibility criteria:
inclusion criteria: * have normal vision * are far-sighted or near-sighted * have no eye diseases subjects aged 18 and over, who have refractive errors ranging from +5.0 to -5.0 and/or who have eye disease will be included in the study.

Keywords: this study tests functional ability of patients with refractive error or normal vision while using different types of eyeglasses.